Pharmacogenetics of cytotoxic drugs

Expert Review of Anticancer Therapy

Volumn 1, Issue 2, 2001, Pages 301-308

  Daly, Ann K ^a   Hall, Andrew G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

5 fluorouracil; 6 mercaptopurine; Acetyltransferase; Amonafide; Cyclophosphamide; Cytochrome P450; Dehydrogenase; Drug transporter; Etoposide; Genetic polymorphism; Genotype; Glutathione S transferase; Ifosphamide; Irinotecan; Methyltransferase; Paclitaxel; UDP glucuronosyltransferase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACYLTRANSFERASE; AMONAFIDE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; CYTOTOXIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; GYRASE INHIBITOR; IFOSFAMIDE; INTERCALATING AGENT; IRINOTECAN; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PHOSPHORAMIDE MUSTARD; QUINONE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; UNINDEXED DRUG; VINCA ALKALOID;

BONE MARROW SUPPRESSION; CONTROLLED STUDY; DNA MICROARRAY; DNA POLYMORPHISM; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; GENETIC ANALYSIS; HUMAN; PHARMACOGENETICS; REVIEW; TUMOR CLASSIFICATION;

EID: 0035560048     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.2.301     Document Type: Review

References (55)

1. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
2. Association of CYP3A4 genotype with treatment-related leukemia
3. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4
4. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
5. Metabolism and pharmacokinetics of oxazaphosphorines
6. Development of a substrate-activity based approach to identify the major human liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P450 profiles
7. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
8. Human cytochrome P4502B6 - Interindividual hepatic expression, substrate specificity and role in procarcinogen activation
9. A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation
10. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
11. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
12. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-Ile359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation
13. Variability in human cytochrome P450 paclitaxel metabolism
14. Allelic frequencies of human CYP2C8 and genetic linkage among different ethnic populations
15. A novel polymorphism in the cytochrome P450 CYP2C8
16. Diagnostic-analysis, clinical importance and molecular-basis of dihydropyrimidine dehydrogenase-deficiency
17. Known variant DPYD alleles do not explain DPD deficiency in cancer patients
18. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
19. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase and epoxide hydrolase enzymes: Relevance to xenobiotic metabolism and toxicity
20. Expression of μ-class glutathione-S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia
21. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia
22. Glutathione and the response of malignant cells to chemotherapy
23. Naturally-occurring human glutathione-S-transferase GSTP1-1 isoforms with isoleucine and valine in position-104 differ in enzymatic-properties
24. Methyltransferase pharmacogenetics
25. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
26. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukemia
27. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase
28. Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism
29. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
30. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
31. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine
32. High incidence of secondary brain tumours after radiotherapy and antimetabolites
33. Genetic predisposition to the metabolism of irinotecan (CPT-11) - Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
34. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
35. Analysis of Genes for bilirubin udp-glucuronosyltransferase in Gilbert's syndrome
36. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
37. Phase-I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute-leukemia
38. Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan
39. An inventory of the human ABC proteins
40. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
41. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects
42. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
43. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
44. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
45. Pharmacogenetics and future drug development and delivery
46. Application of SNP technologies in medicine: Lessons learned and future challenges
47. Searching for genetic determinants in the new millennium
48. How many diseases does it take to map a gene with SNPs?
49. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations
50. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies
51. Molecular basis of ethnic differences in drug disposition and response
52. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
53. Novel mutations of CYP3A4 in Chinese
54. Identification and functional characterization of eight CYP3A4 protein variants